← Back

Wire · opportunities

Roche's next big breast cancer drug, Wilserdly, secures FDA approval as 4th oral SERD

Published

17 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercepharma.com →

◆ Verified

Fusion42 · 17 November 2026 · Fusion42 review

Roche's oral SERD drug Wilserdly (giredestrant) has won FDA approval for use in combination with everolimus for HR-positive, HER2-negative, ESR1-mutated advanced breast cancer. The approval marks Wilserdly as the fourth oral SERD available, competing in a niche second-line setting, while Roche awaits a crucial upcoming FDA decision on its use in the larger adjuvant early-stage breast cancer market.

This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 16 Nov 2026 and 17 Nov 2026.

◆ ◆ The Wire takeaway

Your breast cancer drug efforts face a competitive FDA landscape demanding differentiation through adjuvant trials, not just second-line approvals. Watch Roche's pending adjuvant FDA decision as it will open a far larger patient market and reset commercial priorities.

◆ Coverage

5 sources · first reported 16 Nov 2026 · latest 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechbreast-cancerdrug-approvaloral-serdFDARoche